<DOC>
	<DOCNO>NCT00362310</DOCNO>
	<brief_summary>Recent study describe reduced incidence regression Kaposi 's sarcoma ( KS ) HIV-infected patient treat highly active anti-retroviral therapy ( HAART ) contain least one inhibitor HIV protease ( HIV-PI ) Indinavir . Experimental study show part anti-KS action HIV-PI related antiretroviral action , , least part , capability block angiogenesis tumor growth . This study conduct HIV-negative ( classical ) KS patient prove Indinavir anti-angiogenic anti-KS effect human independently antiretroviral activity .</brief_summary>
	<brief_title>Treatment Classical Non-HIV-Related Kaposi 's Sarcoma With Antiviral Drug Indinavir</brief_title>
	<detailed_description>Kaposi 's sarcoma ( KS ) rare vascular tumor affect elderly individual Mediterranean country ( CKS ) , post transplant patient , increase incidence aggressiveness , HIV-infected individual ( AIDS-KS ) . No definitive cure establish KS conventional therapy result low response rate , high toxicity tumor relapse . Antiretroviral therapy include HIV protease inhibitor ( HIV-PI ) reduce AIDS-KS incidence induce KS regression treat patient . This explain solely drug-mediated HIV suppression immune reconstitution . We show HIV-PI Indinavir Saquinavir block KS-like lesion mice inhibit angiogenesis tumor cell invasion blockade matrix metalloprotease 2 ( MMP2 ) proteolytic activation . Based data , proof-of-concept clinical study HIV-negative ( classic ) KS ( C-KS ) patient plan prove Indinavir anti-angiogenic anti-KS effect human independently antiretroviral activity . Recent concept evaluation non cytotoxic anti-cancer drug anti-angiogenic agent suggest novel criterion design clinical study due specific mechanism action drug . In particular , use conventional evaluation criterion base cytotoxic action may mislead interpretation therapeutic efficacy non cytotoxic agent . The study therefore design compare clinical response Indinavir early-stage vs. late-stage KS relate key biological endpoint plasmatic drug concentration . This also motivated rareness C-KS ethical reason prevent inclusion control group . Patients treat per o 800 mg x 2/daily Indinavir 12 month . Follow-up one year . Primary objective : Evaluation tumor response rate ( complete response , partial response , improved disease stable disease ) indinavir treatment mild severe classical KS patient ; Evaluation duration response indinavir-treated patient . Secondary objective : Evaluation Indinavir safety classical KS population ; Determination pharmacokinetic profile Indinavir ; Evaluation key Kaposi 's sarcoma biological endpoint include marker angiogenesis tumor invasion , Th1 Th2 polarization immune response , immunoactivation , immune response HHV8 , herpesviruses common pathogen .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>Have document diagnosis classical KS Be HIVnegative Be 18 year old Have one following : minimum 3 measurable progressive lesion ; stage complicate KS , i.e . show functional impotency affect limb , lymphedema , lymphorrea pain ; visceral disease ; lack response conventional therapy ( radiotherapy , chemotherapy ) ; contraindication conventional therapy Presence lifethreatening lesion concomitant illness , neoplasia clinical condition threaten health patient compliance treatment Inability provide inform consent Concomitant treatment ( within 30 day initiate study treatment ) systemic immunomodulatory agent ( e.g. , glucocorticoid immunosuppressive agent , interferon ) chemotherapy Pregnancy Impaired clinical condition ( Karnofsky 's index &lt; 60 Diabetes , history nephrolithiasis monolateral nephropathy Difficulty swallow capsules/tablets Any clinically significant laboratory finding obtain screening , include : Alkaline phosphatase ( AP ) &gt; 2 fold upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) Alkaline aminotransferase ( ALT ) Gammaglutamyl transferase ( gammaGT ) total bilirubin &gt; 3 fold ULN Serum creatinine &gt; 1.2 mg/d woman &gt; 1.4 mg/dL men creatinine clearance &gt; 100 +/ 25 Pancreatic amylase &gt; 1.5 fold ULN Hemoglobin &lt; 10.0 g/dL male , &lt; 9.0 g/dL female Platelet count &lt; 75.000/cubic millimeter ( mm3 ) Neutrophil count &lt; 850/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>classical kaposi 's sarcoma</keyword>
	<keyword>treatment</keyword>
	<keyword>HIV protease inhibitor indinavir</keyword>
</DOC>